Weighted-Average Shares Outstanding (Diluted): The number of shares held by shareholders including insiders but not including a company's treasury shares assuming conversion of all convertible debt, securities, warrants and options, sourced from the company 10-K or 10-Q SEC reports.
TransCode Therapeutics Inc. (RNAZ) had Weighted-Average Shares Outstanding (Diluted) of 0.83M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-4.86M |
|
-- |
|
-- |
|
$4.56M |
|
$-4.56M |
|
$-0.29M |
|
$-4.86M |
|
$-4.86M |
|
$-4.86M |
|
$-4.86M |
|
$-4.86M |
|
$-4.86M |
|
$-4.56M |
|
$-4.56M |
|
0.83M |
|
|
Weighted-Average Shares Outstanding (Diluted) |
0.83M |
$-5.82 |
|
$-5.82 |
|
| Balance Sheet Financials | |
$4.75M |
|
$0.02M |
|
$0.48M |
|
$5.23M |
|
$2.97M |
|
-- |
|
$0.83M |
|
$3.80M |
|
$1.43M |
|
$1.43M |
|
$1.43M |
|
0.83M |
|
| Cash Flow Statement Financials | |
$-11.37M |
|
-- |
|
$8.40M |
|
$5.81M |
|
$2.84M |
|
$-2.98M |
|
$0.42M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.60 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-11.37M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-340.54% |
|
-340.54% |
|
-92.91% |
|
-340.54% |
|
$1.71 |
|
$-13.64 |
|
$-13.64 |
|